Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 14/20 | 0.68 |
| ▸ | ABCC1 | P33527 | 7/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17747465 | 0.92 | ABCG2 (0.76) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747435 | 0.90 | ABCG2 (0.83) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747432 | 0.88 | ABCG2 (0.85) | ABCG2ABCC1CHRM4MEN1KMT2A | |
| SCHEMBL17747482 | 0.87 | ABCG2 (0.77) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747481 | 0.86 | ABCG2 (0.73) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747444 | 0.86 | ABCG2 (0.86) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747472 | 0.86 | ABCG2 (0.75) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747434 | 0.84 | ABCG2 (0.62) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747502 | 0.84 | ABCG2 (0.85) | ABCG2ABCC1CHRM4MEN1ALDH1A1 | |
| SCHEMBL17747498 | 0.84 | ABCG2 (0.73) | ABCG2ABCC1CHRM4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908893-B2 | Thieno [2,3-b] pyridines as multidrug resistance modulators | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-03-06 | — | — | US | disclosed |
| US-20160137664-A1 | THIENO [2,3-b] PYRIDINES AS MULTIDRUG RESISTANCE MODULATORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137664-A1 | THIENO [2,3-b] PYRIDINES AS MULTIDRUG RESISTANCE MODULATORS | ABCC1, ABCB1, MT-CO1 | ABCG2 223/4885ABCC1 1/4885CHRM4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.